Company intelligence / Profile preview

Synergy Biologics

Ownership: Private
Development stage: Commercial

Overview

Synergy Biologics has developed a vertically integrated process for sourcing, processing, and distributing amniotic tissue allografts. Their flagship product surgiGRAFT™ has been launched nationwide. The company emphasizes regulatory compliance with FDA/AATB standards and focuses on accessibility and affordability in advanced wound care therapies. Clinical results are not detailed publicly but products are commercially available.

Therapeutic areas: Dermatology
Modalities: Live biotherapeutic product therapy (amniotic tissue allograft)Biologic
Industry: Biotech

Drug pipeline

2 assets

surgiGRAFT AC

Unknown

1 more asset in the full pipeline.

Partnerships

Partnered with hospital systems’ wound care centers, operating rooms, labor & delivery sites for donor recruitment/recoveryGroup purchasing organizations (GPOs) involved in scaling access to products

Beyond the preview

Go deeper on Synergy Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synergy Biologics.